Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 230

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 230
---
,960 |     | $            | 237,547 |

As of December 31, 2023 and 2022, there was $ 231,550and $ 61,111, respectively, of unrecognized stock-based compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of 1.06years and 1.83years, respectively.

| F-40 |

A summary of activity regarding the Restricted Stock Units issued follows:

Schedule of Restricted Stock Units (RSUs)

|                                              |     | Number of Shares |         |   |     | Weighted Average Grant Date Fair Value Per Share |        |
|:---------------------------------------------|:----|:-----------------|--------:|:--|:----|:-------------------------------------------------|-------:|
| Outstanding, December 31, 2021 (as restated) |     |                  |   2,017 |   |     | $                                                | 185.60 |
| Granted                                      |     |                  |   4,449 |   |     |                                                  |  22.48 |
| Vested (as restated)                         |     |                  |  (3,500 | ) |     |                                                  | 116.48 |
| Outstanding, December 31, 2022 (as restated) |     |                  |   2,966 |   |     | $                                                |  22.48 |
| Granted                                      |     |                  |  32,415 |   |     |                                                  |  10.88 |
| Vested (as restated)                         |     |                  | (10,650 | ) |     |                                                  |  12.00 |
| Outstanding, December 31, 2023               |     |                  |  24,731 |   |     | $                                                |  11.76 |

Note 8 – Derivative Liabilities

Fair Value Assumptions Used in Accounting for Derivative Liabilities

ASC 815 requires us to assess the fair market value of derivative liabilities at the end of each reporting period and recognize any change in the fair market value as other income or expense.

Alto Opportunity Master Fund, SPC

In January 2023, in connection with the Alto Convertible Note, the Company issued warrants to purchase 127,260shares of common stock, with an exercise price of $ 18.80per share, valued at inception at $ 1,189,000